niacinamide has been researched along with Obesity in 65 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Current studies aimed at investigating the association between atorvastatin therapy and insulin resistance (IR) appear to be controversial." | 7.96 | Long-term atorvastatin or the combination of atorvastatin and nicotinamide ameliorate insulin resistance and left ventricular diastolic dysfunction in a murine model of obesity. ( Mao, Y; Ning, D; Tang, S; Wang, D; Wang, T; Xiong, T; Yang, X; Zhong, H; Zhu, G, 2020) |
| "Resveratrol improves insulin sensitivity and lowers hepatic glucose production (HGP) in rat models of obesity and diabetes, but the underlying mechanisms for these antidiabetic effects remain elusive." | 7.81 | Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. ( Baur, JA; Breen, DM; Côté, CD; Daljeet, M; Duca, FA; Filippi, BM; Lam, TK; Rasmussen, BA; Zadeh-Tahmasebi, M, 2015) |
| "To investigate nicotinamide's action on glucose metabolism, and the association between niacin consumption and obesity prevalence." | 7.76 | Chronic niacin overload may be involved in the increased prevalence of obesity in US children. ( Bian, FN; Guo, M; Li, D; Liu, QG; Luo, N; Sun, WP; Zhao, ZG; Zhou, SS; Zhou, YM, 2010) |
| "NR supplementation of 1000 mg/d for 6 wk in healthy overweight or obese men and women increased skeletal muscle NAD+ metabolites, affected skeletal muscle acetylcarnitine metabolism, and induced minor changes in body composition and sleeping metabolic rate." | 5.34 | Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. ( Aarts, SABM; Auwerx, J; Connell, NJ; de Wit, VHW; Elfrink, HL; Havekes, B; Hoeks, J; Houtkooper, RH; Lindeboom, L; Lutgens, E; Mevenkamp, J; Moonen, MPB; Phielix, E; Remie, CME; Roumans, KHM; Schomakers, BV; Schrauwen, P; Schrauwen-Hinderling, VB; van de Weijer, T; Zapata-Pérez, R, 2020) |
| "Current studies aimed at investigating the association between atorvastatin therapy and insulin resistance (IR) appear to be controversial." | 3.96 | Long-term atorvastatin or the combination of atorvastatin and nicotinamide ameliorate insulin resistance and left ventricular diastolic dysfunction in a murine model of obesity. ( Mao, Y; Ning, D; Tang, S; Wang, D; Wang, T; Xiong, T; Yang, X; Zhong, H; Zhu, G, 2020) |
| "Resveratrol improves insulin sensitivity and lowers hepatic glucose production (HGP) in rat models of obesity and diabetes, but the underlying mechanisms for these antidiabetic effects remain elusive." | 3.81 | Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. ( Baur, JA; Breen, DM; Côté, CD; Daljeet, M; Duca, FA; Filippi, BM; Lam, TK; Rasmussen, BA; Zadeh-Tahmasebi, M, 2015) |
| "To investigate nicotinamide's action on glucose metabolism, and the association between niacin consumption and obesity prevalence." | 3.76 | Chronic niacin overload may be involved in the increased prevalence of obesity in US children. ( Bian, FN; Guo, M; Li, D; Liu, QG; Luo, N; Sun, WP; Zhao, ZG; Zhou, SS; Zhou, YM, 2010) |
| " No serious adverse events due to NR supplementation were observed and safety blood tests were normal." | 2.87 | A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. ( Brenner, C; Christensen, B; Dollerup, OL; Jessen, N; Møller, N; Ringgaard, S; Schmidt, MS; Stødkilde-Jørgensen, H; Sulek, K; Svart, M; Treebak, JT, 2018) |
| "Patients with manifest type 2 diabetes have a significantly (approximately twofold) higher NNMT expression both in omental and subcutaneous WAT compared with controls." | 2.80 | Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance. ( Blüher, M; Dietrich, A; Kannt, A; Klöting, N; Pfenninger, A; Schön, MR; Teichert, L; Tönjes, A, 2015) |
| "Obesity is a major health problem, and although caloric restriction and exercise are successful strategies to lose adipose tissue in obese individuals, a simultaneous decrease in skeletal muscle mass, negatively effects metabolism and muscle function." | 1.48 | N ( Ahlqvist, E; Almgren, P; Calbet, JAL; de Pablos-Velasco, P; Edlund, A; Ekman, C; Ekström, O; Eliasson, L; Fernandez, C; Groop, L; Hansson, O; Hjort, L; Holmberg, HC; Jörgensen, SW; Martin-Rincon, M; Mattiasson, M; Morales-Alamo, D; Oskolkov, N; Ottosson, F; Pérez-López, A; Perez-Suarez, I; Stenkula, KG; Ström, K; Vaag, A; Wierup, N; Zhou, Y, 2018) |
| "Metformin is a first-line therapeutic option for the treatment of type 2 diabetes, even though its underlying mechanisms of action are relatively unclear." | 1.42 | Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. ( Côté, CD; Duca, FA; Filippi, BM; Lam, TK; Rasmussen, BA; Rutter, GA; Zadeh-Tahmasebi, M, 2015) |
| " Starting from compound 1, oral bioavailability was improved by modifying metabolically unstable sites and reducing molecular weight." | 1.42 | Orally active ghrelin receptor inverse agonists and their actions on a rat obesity model. ( Funami, H; Igawa, Y; Iwaki, T; Kamiide, Y; Kanki, S; Koyama, M; Maruoka, H; Muto, T; Nagahira, A; Shibata, M; Takahashi, B, 2015) |
| "In obesity and type 2 diabetes, Glut4 glucose transporter expression is decreased selectively in adipocytes." | 1.40 | Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. ( Alhonen, L; Asara, JM; Banks, AS; Bhanot, S; Cen, Y; Gong, F; Kahn, BB; Kong, D; Kraus, D; Monia, BP; Peroni, OD; Pirinen, E; Puigserver, P; Pulinilkunnil, TC; Rodgers, JT; Sauve, AA; Wang, YC; Yang, Q; Zhang, L, 2014) |
| "Obesity is characterized by the accumulation of triacylglycerol in adipocytes." | 1.37 | A novel coenzyme A:diacylglycerol acyltransferase 1 inhibitor stimulates lipid metabolism in muscle and lowers weight in animal models of obesity. ( Aicher, TD; Kato, K; Kitamura, S; Miki, H; Nakada, Y; Pratt, SA; Yamaguchi, H; Yamamoto, T, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (13.85) | 18.7374 |
| 1990's | 5 (7.69) | 18.2507 |
| 2000's | 6 (9.23) | 29.6817 |
| 2010's | 30 (46.15) | 24.3611 |
| 2020's | 15 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, C | 1 |
| Yang, C | 1 |
| Wang, X | 1 |
| Chen, Y | 3 |
| Liu, X | 1 |
| Deng, H | 1 |
| Ruf, S | 1 |
| Rajagopal, S | 1 |
| Kadnur, SV | 1 |
| Hallur, MS | 1 |
| Rani, S | 1 |
| Kristam, R | 1 |
| Swaminathan, S | 1 |
| Zope, BR | 1 |
| Gondrala, PK | 1 |
| Swamy, I | 1 |
| Putta, VPRK | 1 |
| Kandan, S | 1 |
| Zech, G | 1 |
| Schreuder, H | 1 |
| Rudolph, C | 1 |
| Elvert, R | 1 |
| Czech, J | 1 |
| Birudukota, S | 1 |
| Siddiqui, MA | 1 |
| Anand, NN | 1 |
| Mane, VS | 1 |
| Dittakavi, S | 1 |
| Suresh, J | 1 |
| Gosu, R | 1 |
| Ramesh, M | 1 |
| Yura, T | 1 |
| Dhakshinamoorthy, S | 1 |
| Kannt, A | 3 |
| Dollerup, OL | 3 |
| Trammell, SAJ | 1 |
| Hartmann, B | 1 |
| Holst, JJ | 1 |
| Christensen, B | 2 |
| Møller, N | 2 |
| Gillum, MP | 1 |
| Treebak, JT | 3 |
| Jessen, N | 3 |
| Shi, W | 2 |
| Hegeman, MA | 2 |
| Doncheva, A | 1 |
| Bekkenkamp-Grovenstein, M | 1 |
| de Boer, VCJ | 1 |
| Keijer, J | 2 |
| Chubanava, S | 1 |
| Agerholm, M | 1 |
| Søndergård, SD | 1 |
| Altıntaş, A | 1 |
| Møller, AB | 1 |
| Høyer, KF | 1 |
| Ringgaard, S | 2 |
| Stødkilde-Jørgensen, H | 2 |
| Lavery, GG | 3 |
| Barrès, R | 1 |
| Larsen, S | 1 |
| Prats, C | 1 |
| Leduc-Gaudet, JP | 1 |
| Dulac, M | 1 |
| Reynaud, O | 1 |
| Ayoub, MB | 1 |
| Gouspillou, G | 1 |
| Zhang, J | 1 |
| Liu, C | 1 |
| Li, L | 2 |
| Li, P | 1 |
| Remie, CME | 1 |
| Roumans, KHM | 1 |
| Moonen, MPB | 1 |
| Connell, NJ | 1 |
| Havekes, B | 1 |
| Mevenkamp, J | 1 |
| Lindeboom, L | 1 |
| de Wit, VHW | 1 |
| van de Weijer, T | 1 |
| Aarts, SABM | 1 |
| Lutgens, E | 1 |
| Schomakers, BV | 1 |
| Elfrink, HL | 1 |
| Zapata-Pérez, R | 1 |
| Houtkooper, RH | 2 |
| Auwerx, J | 2 |
| Hoeks, J | 1 |
| Schrauwen-Hinderling, VB | 1 |
| Phielix, E | 1 |
| Schrauwen, P | 1 |
| Fluharty, NT | 1 |
| Brenner, C | 3 |
| Moore, MP | 1 |
| Mucinski, JM | 1 |
| Yang, X | 1 |
| Xiong, T | 1 |
| Ning, D | 1 |
| Wang, T | 1 |
| Zhong, H | 1 |
| Tang, S | 1 |
| Mao, Y | 1 |
| Zhu, G | 1 |
| Wang, D | 1 |
| Ibrahim, GR | 1 |
| Shah, I | 1 |
| Gariballa, S | 1 |
| Yasin, J | 1 |
| Barker, J | 1 |
| Salman Ashraf, S | 1 |
| de Castro, JM | 1 |
| Assumpção, JAF | 1 |
| Stein, DJ | 1 |
| Toledo, RS | 1 |
| da Silva, LS | 1 |
| Caumo, W | 1 |
| Carraro, CC | 1 |
| da Rosa Araujo, AS | 1 |
| Torres, ILS | 1 |
| Hardy, RS | 1 |
| Botfield, H | 1 |
| Markey, K | 1 |
| Mitchell, JL | 1 |
| Alimajstorovic, Z | 1 |
| Westgate, CSJ | 1 |
| Sagmeister, M | 1 |
| Fairclough, RJ | 1 |
| Ottridge, RS | 1 |
| Yiangou, A | 1 |
| Storbeck, KH | 1 |
| Taylor, AE | 1 |
| Gilligan, LC | 1 |
| Arlt, W | 1 |
| Stewart, PM | 1 |
| Tomlinson, JW | 1 |
| Mollan, SP | 1 |
| Sinclair, AJ | 1 |
| Roberti, A | 1 |
| Fernández, AF | 1 |
| Fraga, MF | 1 |
| Méndez-Lara, KA | 1 |
| Rodríguez-Millán, E | 1 |
| Sebastián, D | 1 |
| Blanco-Soto, R | 1 |
| Camacho, M | 1 |
| Nan, MN | 1 |
| Diarte-Añazco, EMG | 1 |
| Mato, E | 1 |
| Lope-Piedrafita, S | 1 |
| Roglans, N | 1 |
| Laguna, JC | 1 |
| Alonso, N | 1 |
| Mauricio, D | 1 |
| Zorzano, A | 1 |
| Villarroya, F | 1 |
| Villena, JA | 1 |
| Blanco-Vaca, F | 1 |
| Julve, J | 1 |
| Cartwright, DM | 1 |
| Oakey, LA | 1 |
| Fletcher, RS | 1 |
| Doig, CL | 1 |
| Heising, S | 1 |
| Larner, DP | 1 |
| Nasteska, D | 1 |
| Berry, CE | 1 |
| Heaselgrave, SR | 1 |
| Ludwig, C | 1 |
| Hodson, DJ | 1 |
| Garten, A | 1 |
| Ström, K | 1 |
| Morales-Alamo, D | 1 |
| Ottosson, F | 1 |
| Edlund, A | 1 |
| Hjort, L | 1 |
| Jörgensen, SW | 1 |
| Almgren, P | 1 |
| Zhou, Y | 3 |
| Martin-Rincon, M | 1 |
| Ekman, C | 1 |
| Pérez-López, A | 1 |
| Ekström, O | 1 |
| Perez-Suarez, I | 1 |
| Mattiasson, M | 1 |
| de Pablos-Velasco, P | 1 |
| Oskolkov, N | 1 |
| Ahlqvist, E | 1 |
| Wierup, N | 1 |
| Eliasson, L | 1 |
| Vaag, A | 1 |
| Groop, L | 1 |
| Stenkula, KG | 1 |
| Fernandez, C | 1 |
| Calbet, JAL | 1 |
| Holmberg, HC | 1 |
| Hansson, O | 1 |
| Kazemi, F | 1 |
| Zahediasl, S | 1 |
| Svart, M | 1 |
| Schmidt, MS | 1 |
| Sulek, K | 1 |
| Ying, HZ | 1 |
| Zang, JN | 1 |
| Deng, LL | 1 |
| Wang, ZY | 1 |
| Yu, CH | 1 |
| Yang, SJ | 2 |
| Choi, JM | 1 |
| Kim, L | 1 |
| Park, SE | 1 |
| Rhee, EJ | 1 |
| Lee, WY | 1 |
| Oh, KW | 1 |
| Park, SW | 1 |
| Park, CY | 1 |
| Kraus, D | 1 |
| Yang, Q | 3 |
| Kong, D | 1 |
| Banks, AS | 1 |
| Zhang, L | 1 |
| Rodgers, JT | 1 |
| Pirinen, E | 2 |
| Pulinilkunnil, TC | 1 |
| Gong, F | 1 |
| Wang, YC | 1 |
| Cen, Y | 2 |
| Sauve, AA | 2 |
| Asara, JM | 1 |
| Peroni, OD | 1 |
| Monia, BP | 1 |
| Bhanot, S | 1 |
| Alhonen, L | 1 |
| Puigserver, P | 1 |
| Kahn, BB | 1 |
| Pfenninger, A | 2 |
| Teichert, L | 1 |
| Tönjes, A | 2 |
| Dietrich, A | 1 |
| Schön, MR | 1 |
| Klöting, N | 1 |
| Blüher, M | 2 |
| Côté, CD | 2 |
| Rasmussen, BA | 2 |
| Duca, FA | 2 |
| Zadeh-Tahmasebi, M | 2 |
| Baur, JA | 1 |
| Daljeet, M | 1 |
| Breen, DM | 1 |
| Filippi, BM | 2 |
| Lam, TK | 2 |
| Rutter, GA | 1 |
| Koh, EH | 1 |
| Kim, AR | 1 |
| Kim, H | 1 |
| Kim, JH | 1 |
| Park, HS | 1 |
| Ko, MS | 1 |
| Kim, MO | 1 |
| Kim, HJ | 1 |
| Kim, BJ | 1 |
| Yoo, HJ | 1 |
| Kim, SJ | 1 |
| Oh, JS | 1 |
| Woo, CY | 1 |
| Jang, JE | 1 |
| Leem, J | 1 |
| Cho, MH | 1 |
| Lee, KU | 1 |
| Lee, HJ | 1 |
| Hong, YS | 1 |
| Jun, W | 1 |
| Takahashi, B | 2 |
| Funami, H | 2 |
| Iwaki, T | 2 |
| Maruoka, H | 2 |
| Nagahira, A | 2 |
| Koyama, M | 2 |
| Kamiide, Y | 2 |
| Matsuo, T | 1 |
| Muto, T | 2 |
| Annoura, H | 1 |
| Liu, M | 3 |
| Chu, J | 2 |
| Zhu, B | 1 |
| Zhang, Q | 1 |
| Yin, X | 1 |
| Jiang, W | 1 |
| Dai, G | 1 |
| Ju, W | 2 |
| Wang, Z | 2 |
| Fang, Z | 1 |
| Shibata, M | 1 |
| Kanki, S | 1 |
| Igawa, Y | 1 |
| Zhou, SS | 3 |
| Li, D | 3 |
| Fang, ZY | 1 |
| Trammell, SA | 1 |
| Weidemann, BJ | 1 |
| Chadda, A | 1 |
| Yorek, MS | 1 |
| Holmes, A | 1 |
| Coppey, LJ | 1 |
| Obrosov, A | 1 |
| Kardon, RH | 1 |
| Yorek, MA | 1 |
| Liu, Z | 1 |
| Gan, L | 1 |
| Liu, G | 1 |
| Wu, T | 1 |
| Feng, F | 1 |
| Sun, C | 1 |
| Qi, Z | 1 |
| Xia, J | 1 |
| Xue, X | 1 |
| He, Q | 1 |
| Ji, L | 1 |
| Ding, S | 1 |
| Gu, Y | 1 |
| Shi, H | 1 |
| Zhang, R | 1 |
| Wang, L | 1 |
| Chen, J | 1 |
| Shen, L | 1 |
| Yu, P | 1 |
| Chen, X | 1 |
| van Dartel, DAM | 1 |
| Tang, J | 1 |
| Suarez, M | 1 |
| Swarts, H | 1 |
| van der Hee, B | 1 |
| Arola, L | 1 |
| Varela, M | 1 |
| Reig, M | 1 |
| de la Mata, M | 1 |
| Matilla, A | 1 |
| Bustamante, J | 1 |
| Pascual, S | 1 |
| Turnes, J | 1 |
| Aracil, C | 1 |
| Del Val, A | 1 |
| Pascasio, JM | 1 |
| Rodríguez, M | 1 |
| Bruix, J | 1 |
| Sun, WP | 1 |
| Zhou, YM | 1 |
| Liu, QG | 1 |
| Luo, N | 1 |
| Bian, FN | 1 |
| Zhao, ZG | 1 |
| Guo, M | 1 |
| Yamamoto, T | 1 |
| Yamaguchi, H | 1 |
| Miki, H | 1 |
| Kitamura, S | 1 |
| Nakada, Y | 1 |
| Aicher, TD | 1 |
| Pratt, SA | 1 |
| Kato, K | 1 |
| Zhang, LN | 1 |
| Vincelette, J | 1 |
| Chen, D | 1 |
| Gless, RD | 1 |
| Anandan, SK | 1 |
| Rubanyi, GM | 1 |
| Webb, HK | 1 |
| MacIntyre, DE | 1 |
| Wang, YX | 1 |
| Cantó, C | 1 |
| Youn, DY | 1 |
| Oosterveer, MH | 1 |
| Fernandez-Marcos, PJ | 1 |
| Yamamoto, H | 1 |
| Andreux, PA | 1 |
| Cettour-Rose, P | 1 |
| Gademann, K | 1 |
| Rinsch, C | 1 |
| Schoonjans, K | 1 |
| Pachocka, L | 1 |
| Kłosiewicz-Latoszek, L | 1 |
| Broca, C | 1 |
| Breil, V | 1 |
| Cruciani-Guglielmacci, C | 1 |
| Manteghetti, M | 1 |
| Rouault, C | 1 |
| Derouet, M | 1 |
| Rizkalla, S | 1 |
| Pau, B | 1 |
| Petit, P | 1 |
| Ribes, G | 1 |
| Ktorza, A | 1 |
| Gross, R | 1 |
| Reach, G | 1 |
| Taouis, M | 1 |
| Larsen, MO | 2 |
| Juhl, CB | 1 |
| Pørksen, N | 2 |
| Gotfredsen, CF | 2 |
| Carr, RD | 2 |
| Ribel, U | 1 |
| Wilken, M | 2 |
| Rolin, B | 2 |
| Sturis, J | 1 |
| Dawson, B | 1 |
| Favaloro, EJ | 1 |
| Taylor, J | 1 |
| Aggarwal, A | 1 |
| Wu, X | 1 |
| Wang, M | 1 |
| Unger, RH | 2 |
| Zhu, M | 2 |
| Noma, Y | 1 |
| Mizuno, A | 1 |
| Sano, T | 1 |
| Shima, K | 2 |
| Shimabukuro, M | 1 |
| Ohneda, M | 1 |
| Lee, Y | 1 |
| Ogino, T | 1 |
| Murakami, T | 1 |
| Kuwajima, M | 1 |
| Piercy, V | 1 |
| Toseland, CD | 1 |
| Turner, NC | 1 |
| Johnson, JT | 3 |
| Kaplan, ML | 1 |
| Leveille, GA | 1 |
| Van Twisk, P | 1 |
| Braĭko, IV | 1 |
| Renzetti, AR | 1 |
| Criscuoli, M | 1 |
| Subissi, A | 1 |
| Tochino, Y | 1 |
| Obrosova, IG | 1 |
| Kirput', SN | 1 |
| Ostrovskiĭ, IuM | 1 |
| Larin, FS | 1 |
| Efimov, AS | 1 |
| Mickelsen, O | 2 |
| Hook, JB | 2 |
| Gunnarsson, R | 1 |
| Berne, C | 1 |
| Hellerström, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Nicotinamide Ribose (NR) on Substrate Metabolism, Insulin Sensitivity, and Body Composition in Obese Men - a Randomized, Placebo Controlled Clinical Trial[NCT02303483] | 40 participants (Actual) | Interventional | 2016-01-04 | Completed | |||
| Effects of Nicotinamide Riboside on Metabolic Health in (Pre)Obese Humans[NCT02835664] | 15 participants (Actual) | Interventional | 2016-12-31 | Completed | |||
| Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the Therapeutic Efficacy and Safety of an 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017). Phase II Study.[NCT02017444] | Phase 2 | 31 participants (Actual) | Interventional | 2014-04-25 | Completed | ||
| Center-Based and Home-Based Walking Exercise Intervention to Reduce Fatigue in Older Breast Cancer Survivors[NCT05684367] | 24 participants (Anticipated) | Interventional | 2023-11-29 | Recruiting | |||
| NOPARK Open Label Extension Study[NCT05546567] | 400 participants (Anticipated) | Interventional | 2022-09-28 | Recruiting | |||
| Vitamin B3 as a Novel Mitochondrial Therapy for Obesity[NCT03951285] | 56 participants (Actual) | Interventional | 2016-05-25 | Completed | |||
| Nicotinamide Riboside (NR) in Paclitaxel-induced Peripheral Neuropathy[NCT03642990] | Phase 2 | 5 participants (Actual) | Interventional | 2019-11-08 | Terminated (stopped due to Enrollment challenges) | ||
| Validation of an Enzymatic Assay for Quantification of Nicotinamide Adenine Dinucleotide in Blood Plasma After Ingestion of the Vitamin B3 Variant Nicotinamide Riboside: a Randomized Controlled Trial[NCT06005350] | 54 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | |||
| Study to Evaluate the Effect of Nicotinamide Riboside on Immunity[NCT02812238] | 38 participants (Actual) | Interventional | 2016-06-23 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The safety and tolerability profile of AZD4017 in female patients with IIH through adverse event reporting and safety bloods. (NCT02017444)
Timeframe: 16 weeks
| Intervention | AEs related to intervention (Number) |
|---|---|
| Placebo | 0 |
| AZD4017 (11b-HSD1 Inhibitor) | 9 |
The temporal change in Body Mass Index (in kg/m^2) over 12 weeks of treatment, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | kg/m^2 (Mean) |
|---|---|
| Placebo | 37.4 |
| AZD4017 (11b-HSD1 Inhibitor) | 37.5 |
The change in headache associated disability through the headache impact test-6 score (HIT 6), measured at baseline and week 12. This is scored 11-66 with higher scores indicating worse headache. (NCT02017444)
Timeframe: 12 weeks
| Intervention | Score on HIT-6 scale (Mean) |
|---|---|
| Placebo | 59.8 |
| AZD4017 (11b-HSD1 Inhibitor) | 60.1 |
ICP measured by lumbar puncture in cmCSF as the change from week 0 and week 12 of treatment, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | cmCSF (Mean) |
|---|---|
| Placebo | -0.3 |
| AZD4017 (11b-HSD1 Inhibitor) | -4.3 |
The safety and tolerability profile of AZD4017 in female patients with IIH through adverse event reporting and safety bloods. (NCT02017444)
Timeframe: 16 weeks
| Intervention | Serious adverse events (Number) |
|---|---|
| Placebo | 1 |
| AZD4017 (11b-HSD1 Inhibitor) | 0 |
The temporal change in IIH symptoms (presence or absence of diplopia, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Presence | Absence | |
| AZD4017 (11b-HSD1 Inhibitor) | 2 | 15 |
| Placebo | 1 | 11 |
The temporal change in IIH symptoms (presence or absence of headache, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Presence | Absence | |
| AZD4017 (11b-HSD1 Inhibitor) | 13 | 4 |
| Placebo | 10 | 2 |
The temporal change in IIH visual function in both eyes using a Pelli-Robson chart to evaluate log contrast sensitivity between the baseline to week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Log contrast senstivity (Mean) | |
|---|---|---|
| Baseline LCS worst eye | Week 12 LCS worst eye | |
| AZD4017 (11b-HSD1 Inhibitor) | 1.63 | 1.65 |
| Placebo | 1.63 | 1.66 |
The temporal change in OCT Total average retinal nerve fibre layer thickness (μm), measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | μm (Mean) | |
|---|---|---|
| Total average retinal nerve fibre layer baseline worst ete | Total average retinal nerve fibre layer week 12 worst eye | |
| AZD4017 (11b-HSD1 Inhibitor) | 152 | 139.7 |
| Placebo | 158.4 | 143.2 |
"The temporal change in papilloedema (evaluated at the end of trial follow up using stereoscopic fundus photographs by masked neuro-ophthalmologists to grade the images according to Frisen classification) measured at baseline and week 12. There are 6 grades, 0-5, 5 being the worst.~The modified Frisén scale for grading papilledema using fundus photography is as follows:~Grade 1 - C-Shaped halo with a temporal gap~Grade 2 - The halo becomes circumferential~Grade 3 - Loss of major vessels as they leave the disc~Grade 4 - Loss of major vessels on the disc~Grade 5 - Criteria of Grade IV + partial or total obscuration of all vessels on the disc~For further details see e.g. Scott, C.J., et al., Diagnosis and grading of papilledema in patients with raised intracranial pressure using optical coherence tomography vs clinical expert assessment using a clinical staging scale. Arch. Ophthalmol, 2010. 128(6): p. 705-711." (NCT02017444)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Frisen grade 0 baseline | Frisen grade 0 week 12 | Frisen grade 1 baseline | Frisen grade 1 week 12 | Frisen grade 2 baseline | Frisen grade 2 week 12 | Frisen grade 3 baseline | Frisen grade 3 week 12 | Frisen grade 4 baseline | Frisen grade 4 week 12 | Frisen grade 5 baseline | Frisen grade 5 week 12 | |
| AZD4017 (11b-HSD1 Inhibitor) | 0 | 2 | 4 | 5 | 9 | 8 | 0 | 0 | 2 | 1 | 1 | 0 |
| Placebo | 0 | 0 | 2 | 2 | 5 | 6 | 3 | 3 | 1 | 1 | 0 | 0 |
The temporal change in IIH symptoms (presence or absence of tinnitus), measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Presence | Absence | |
| AZD4017 (11b-HSD1 Inhibitor) | 9 | 8 |
| Placebo | 7 | 5 |
The temporal change in IIH visual function in both eyes (measured by LogMAR (log of the minimum angle of resolution) chart to assess visual acuity, between the baseline to week 12, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | LogMAR (log of the minimum angle of reso (Mean) | |
|---|---|---|
| Baseline LVA worst eye | Week 12 LVA worst eye | |
| AZD4017 (11b-HSD1 Inhibitor) | 0.08 | 0.06 |
| Placebo | 0.13 | 0.09 |
The temporal change in IIH visual function in both eyes using automated perimetry (Humphrey 24-2 central threshold) to measure the visual field mean deviation between the baseline to week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Visual field mean deviation (Mean) | |
|---|---|---|
| Baseline MD worst eye | Week 12 MD worst eye | |
| AZD4017 (11b-HSD1 Inhibitor) | -6.1 | -3.4 |
| Placebo | -3.4 | -2.2 |
The temporal change in IIH symptoms (presence or absence of visual loss, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Presence | Absence | |
| AZD4017 (11b-HSD1 Inhibitor) | 6 | 11 |
| Placebo | 7 | 4 |
The temporal change in IIH symptoms (presence or absence of visual obscuration, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Presence | Absence | |
| AZD4017 (11b-HSD1 Inhibitor) | 2 | 15 |
| Placebo | 2 | 9 |
Difference in Score on the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity questionnaire at the end of treatment; i.e. Score at screening - score at end of treatment. This questionnaire asks 11 questions that are specific to chemotherapy-induced peripheral neuropathies. Maximum score is 44, minimum score is 0. Positive differences indicate a decrease in neuropathy. Negative differences indicate a worsening of neuropathy. Zero means unchanged. (NCT03642990)
Timeframe: 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| NIAGEN®) | 7 |
Exploratory analysis of ability of the clinical version of the Total Neuropathy Score questionnaire to detect changes in CIPN severity over time. Unlike the CTCAE or the FACT&GOG-NTX questionnaires, the TNS is a patient reported outcome measure. HIghest score (worse neuropathy is 24, lowest score is 0. Outcome assessed difference between end of treatment and screening. A positive number indicates improvement in neuropathy (NCT03642990)
Timeframe: 4 weeks
| Intervention | score on a scale (Median) |
|---|---|
| NIAGEN®) | 2 |
Count the number of (i.e. the incidence) of dose reduction events due to neuropathy (each occasion of dose reduction is a separate event); (NCT03642990)
Timeframe: 3 weeks
| Intervention | event (Number) |
|---|---|
| NIAGEN®) | 0 |
"The primary outcome variable is defined as no worsening of the grade of peripheral sensory neuropathy as scored according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 guidelines. Per the CTCAE a score of 1 would be assigned in the instance of parethesias or a loss of deep tendon reflexes. A score of 2 would be assigned in the instance of moderate symptoms that limit instrumental activities of daily living. A score of 3 would be assigned in the instance of severe symptoms that limit self-care activities of daily living. Because the outcome measure is defined as no worsening of the grade, it was recorded as either yes( i.e. it worsened) or no (i.e. it did not worsen)." (NCT03642990)
Timeframe: approximately 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| NIAGEN®) | 3 |
Quantitate the percentage of patients that experience a dose reduction of paclitaxel or nab-paclitaxel therapy due to neuropathy. (NCT03642990)
Timeframe: 3 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| NIAGEN®) | 0 |
Paclitaxel levels in plasma were measured ~30 min after each infusion of taxane. This was undertaken to ascertain whether NIAGEN altered plasma levels of paclitaxel because increases or decreases in plasma levels of paclitaxel by itself could lead to an apparent worsening or improvement, respectively, in CIPN and confound interpretation of NIAGEN's effect. (NCT03642990)
Timeframe: up to 3 weeks
| Intervention | ng/ml (Median) |
|---|---|
| NIAGEN®) | 810 |
Quantitate the total cumulative dose of paclitaxel administered over the 12 weeks. (NCT03642990)
Timeframe: 3 weeks
| Intervention | mg/M^2 (Number) |
|---|---|
| NIAGEN®) | 200 |
The IL- 1beta secretion is measured in response to fasting, refeeding and administration of Nicotinamide Riboside (or placebo). Nicotinamide riboside acts as a fasting mimetic, and is supposed to maintain the reduction of IL-1 beta secretion (indicating NLRP3 inflammasome activation) induced by fasting. 1000 mg of Nicotinamide riboside on a daily basis is given to the subjects for a period of 7-10 days. (NCT02812238)
Timeframe: 4 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Nicotinamide Riboside | 582 |
| Placebo | 794 |
3 reviews available for niacinamide and Obesity
| Article | Year |
|---|---|
Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation.
Topics: Adipose Tissue; Animals; Epigenesis, Genetic; Humans; Insulin Resistance; Liver; NAD; Neoplasms; Nia | 2021 |
Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications.
Topics: Acyl Coenzyme A; Adipocytes; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; F | 1995 |
The NOD mouse as a model of type I diabetes.
Topics: Animals; Autoimmune Diseases; Diabetes Mellitus, Experimental; Female; Gonadal Steroid Hormones; Imm | 1987 |
6 trials available for niacinamide and Obesity
| Article | Year |
|---|---|
Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity.
Topics: Blood Glucose; C-Peptide; Double-Blind Method; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Li | 2019 |
Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men.
Topics: Humans; Insulin Resistance; Male; Middle Aged; Mitochondria, Muscle; Muscle, Skeletal; NAD; Niacinam | 2020 |
Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans.
Topics: Acetylcarnitine; Aged; Body Composition; Dietary Supplements; Female; Humans; Male; Middle Aged; Mus | 2020 |
11βHSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adolescent; Adult; Body Composition; Double-Blind Metho | 2021 |
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re | 2018 |
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re | 2018 |
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re | 2018 |
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re | 2018 |
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re | 2018 |
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re | 2018 |
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re | 2018 |
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re | 2018 |
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re | 2018 |
Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance.
Topics: Adult; Aged; Bariatric Surgery; Biomarkers; Case-Control Studies; Cross-Sectional Studies; Diabetes | 2015 |
56 other studies available for niacinamide and Obesity
| Article | Year |
|---|---|
Nicotinamide reprograms adipose cellular metabolism and increases mitochondrial biogenesis to ameliorate obesity.
Topics: Adipose Tissue; Animals; Glucose; Mice; NAD; Niacinamide; Nicotinamide Phosphoribosyltransferase; Ob | 2022 |
Novel tricyclic small molecule inhibitors of Nicotinamide N-methyltransferase for the treatment of metabolic disorders.
Topics: Animals; Glucose; Humans; Metabolic Diseases; Mice; Niacinamide; Nicotinamide N-Methyltransferase; O | 2022 |
High Dose of Dietary Nicotinamide Riboside Induces Glucose Intolerance and White Adipose Tissue Dysfunction in Mice Fed a Mildly Obesogenic Diet.
Topics: Adipose Tissue, White; Animals; Blood Glucose; Diet, High-Fat; Dose-Response Relationship, Drug; Ene | 2019 |
Nicotinamide riboside supplementation to improve skeletal muscle mitochondrial health and whole-body glucose homeostasis: does it actually work in humans?
Topics: Dietary Supplements; Glucose; Homeostasis; Humans; Insulin; Male; Muscle, Skeletal; Niacinamide; Obe | 2020 |
N
Topics: Acetylation; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Forkhead Box Protein O1; | 2020 |
Fat mobilization without weight loss is a potentially rapid response to nicotinamide riboside in obese people: it's time to test with exercise.
Topics: Acetylcarnitine; Body Composition; Dietary Supplements; Humans; Muscle, Skeletal; Niacinamide; Obesi | 2020 |
Impact of nicotinamide riboside supplementation on skeletal muscle mitochondria and whole-body glucose homeostasis: challenging the current hypothesis.
Topics: Dietary Supplements; Glucose; Homeostasis; Humans; Insulin; Male; Mitochondria, Muscle; Muscle, Skel | 2020 |
Long-term atorvastatin or the combination of atorvastatin and nicotinamide ameliorate insulin resistance and left ventricular diastolic dysfunction in a murine model of obesity.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diet, High-Fat; Drug Therapy, Combin | 2020 |
Significantly Elevated Levels of Plasma Nicotinamide, Pyridoxal, and Pyridoxamine Phosphate Levels in Obese Emirati Population: A Cross-Sectional Study.
Topics: Adolescent; Adult; Biomarkers; Chromatography, Liquid; Cross-Sectional Studies; Female; Humans; Male | 2020 |
Nicotinamide riboside reduces cardiometabolic risk factors and modulates cardiac oxidative stress in obese Wistar rats under caloric restriction.
Topics: Animals; Antioxidants; Caloric Restriction; Cardiometabolic Risk Factors; Insulin Resistance; Male; | 2020 |
Nicotinamide Protects Against Diet-Induced Body Weight Gain, Increases Energy Expenditure, and Induces White Adipose Tissue Beiging.
Topics: Adipocytes, Beige; Adipose Tissue, Brown; Adipose Tissue, White; AMP-Activated Protein Kinases; Anim | 2021 |
Nicotinamide riboside has minimal impact on energy metabolism in mouse models of mild obesity.
Topics: Animals; Cell Respiration; Diet, High-Fat; Disease Models, Animal; Drug Evaluation; Energy Metabolis | 2021 |
N
Topics: Adult; Body Mass Index; Caloric Restriction; Cells, Cultured; Energy Metabolism; Exercise; Exercise | 2018 |
Effects of exercise training on adipose tissue apelin expression in streptozotocin-nicotinamide induced diabetic rats.
Topics: Adipose Tissue; Animals; Apelin; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabet | 2018 |
Pentamethylquercetin reduces fat deposition via Sirt1-mediated pathways in male obese mice induced by a high fat diet.
Topics: Adipogenesis; Adipose Tissue; Adipose Tissue, White; Animals; Diet, High-Fat; Gene Expression Regula | 2013 |
Nicotinamide improves glucose metabolism and affects the hepatic NAD-sirtuin pathway in a rodent model of obesity and type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, | 2014 |
Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.
Topics: Acetyltransferases; Adipocytes; Adipose Tissue; Adipose Tissue, White; Animals; Diabetes Mellitus, T | 2014 |
Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus; Disease Models, Animal; Gene Expression Reg | 2015 |
Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Duodenum; Gene Exp | 2015 |
11β-HSD1 reduces metabolic efficacy and adiponectin synthesis in hypertrophic adipocytes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3-L1 Cells; Adamantane; Adiponectin; Adipose Tissue, | 2015 |
Nicotinamide Riboside Ameliorates Hepatic Metaflammation by Modulating NLRP3 Inflammasome in a Rodent Model of Type 2 Diabetes.
Topics: Adiponectin; Animals; Anti-Inflammatory Agents; Apoptosis Regulatory Proteins; Blood Glucose; CARD S | 2015 |
2-Aminoalkyl nicotinamide derivatives as pure inverse agonists of the ghrelin receptor.
Topics: Animals; Anti-Obesity Agents; Appetite Regulation; Drug Design; HEK293 Cells; High-Throughput Screen | 2015 |
Serum N(1)-Methylnicotinamide Is Associated With Obesity and Diabetes in Chinese.
Topics: Adult; Asian People; Body Mass Index; China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fem | 2015 |
Orally active ghrelin receptor inverse agonists and their actions on a rat obesity model.
Topics: Administration, Oral; Animals; Anti-Obesity Agents; Disease Models, Animal; Drug Inverse Agonism; Ha | 2015 |
Management of nicotinamide N-methyltransferase overexpression: inhibit the enzyme or reduce nicotinamide intake? Reply to Zhou S, Li D, Zhou Y [letter].
Topics: Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Male; Niacinamide; Nicotinamide N-Met | 2015 |
Management of nicotinamide N-methyltransferase overexpression: inhibit the enzyme or reduce nicotinamide intake?
Topics: Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Male; Niacinamide; Nicotinamide N-Met | 2015 |
Letter to the Editor: High Serum N(1)-Methylnicotinamide in Obesity and Diabetes: A Consequence of Excess Nicotinamide?
Topics: Diabetes Mellitus, Type 2; Female; Humans; Male; Niacinamide; Obesity | 2015 |
Response to the Letter by Zhou, et al.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Male; Niacinamide; Obesity | 2015 |
Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice.
Topics: Animals; Blood Glucose; Cornea; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-F | 2016 |
Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice.
Topics: Animals; Blood Glucose; Cornea; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-F | 2016 |
Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice.
Topics: Animals; Blood Glucose; Cornea; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-F | 2016 |
Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice.
Topics: Animals; Blood Glucose; Cornea; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-F | 2016 |
Sirt1 decreased adipose inflammation by interacting with Akt2 and inhibiting mTOR/S6K1 pathway in mice.
Topics: Adaptor Proteins, Signal Transducing; Animals; Anti-Obesity Agents; Cells, Cultured; Diet, High-Fat; | 2016 |
Long-term treatment with nicotinamide induces glucose intolerance and skeletal muscle lipotoxicity in normal chow-fed mice: compared to diet-induced obesity.
Topics: Animals; Antioxidants; Autophagy; Diet, High-Fat; Dietary Supplements; Gene Expression Regulation; G | 2016 |
Serum N1-Methylnicotinamide is Associated With Coronary Artery Disease in Chinese Patients.
Topics: Aged; Biomarkers; Body Mass Index; China; Chromatography, Liquid; Comorbidity; Coronary Angiography; | 2017 |
Effects of a wide range of dietary nicotinamide riboside (NR) concentrations on metabolic flexibility and white adipose tissue (WAT) of mice fed a mildly obesogenic diet.
Topics: Adipokines; Adipose Tissue, White; Animals; Blood Glucose; Carbohydrate Metabolism; Diet; Dietary Su | 2017 |
[Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2010 |
Chronic niacin overload may be involved in the increased prevalence of obesity in US children.
Topics: Adolescent; Adult; Appetite; Biomarkers; Blood Glucose; Child; Child, Preschool; Feeding Behavior; G | 2010 |
A novel coenzyme A:diacylglycerol acyltransferase 1 inhibitor stimulates lipid metabolism in muscle and lowers weight in animal models of obesity.
Topics: Adipose Tissue; Animals; Body Weight; Diacylglycerol O-Acyltransferase; Dietary Carbohydrates; Dieta | 2011 |
Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension.
Topics: Adamantane; Administration, Oral; Animals; Aorta; Diabetes Mellitus, Experimental; Diabetes Mellitus | 2011 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr | 2012 |
[Changes in vitamins intake in overweight and obese adults after low-energy diets].
Topics: Adult; Ascorbic Acid; Avitaminosis; Diet Records; Diet Surveys; Diet, Fat-Restricted; Female; Humans | 2002 |
Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat.
Topics: Animals; Diabetes Mellitus, Experimental; Diet; Enzyme Activation; Glucose; Glucose Clamp Technique; | 2004 |
Beta-cell function and islet morphology in normal, obese, and obese beta-cell mass-reduced Göttingen minipigs.
Topics: Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Experimental; Dietary Fats; Insulin; Ins | 2005 |
Measurements of insulin responses as predictive markers of pancreatic beta-cell mass in normal and beta-cell-reduced lean and obese Göttingen minipigs in vivo.
Topics: Animals; Arginine; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Glucose Tolerance Te | 2006 |
Unrecognized pellagra masquerading as odynophagia.
Topics: Aged; Deglutition Disorders; Diagnostic Errors; Female; Humans; Niacinamide; Obesity; Pellagra; Prea | 2006 |
Dietary nicotinamide supplementation increases xanthine oxidoreductase activity in the kidney and heart but not liver of obese Zucker rats.
Topics: Animals; Female; Food, Fortified; Heart; Kidney; Liver; Myocardium; Niacinamide; Obesity; Organ Size | 1995 |
Poor capacity for proliferation of pancreatic beta-cells in Otsuka-Long-Evans-Tokushima Fatty rat: a model of spontaneous NIDDM.
Topics: Animals; Blood Glucose; Body Weight; Cell Division; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fe | 1996 |
Role of nitric oxide in obesity-induced beta cell disease.
Topics: Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, | 1997 |
Effect of partial pancreatectomy on beta-cell mass in the remnant pancreas of Wistar fatty rats.
Topics: Animals; Blood Glucose; Cell Division; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, | 1998 |
Acceleration of the development of diabetes in obese diabetic (db/db) mice by nicotinamide: a comparison with its antidiabetic effects in non-obese diabetic mice.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Progression; Female; Glycosuria; Hyperglycemia; Insulin; | 2000 |
Renal transport of organic acids and bases in genetically obese mice.
Topics: Acetates; Aminohippuric Acids; Animals; Body Weight; Disease Models, Animal; Female; Hyperglycemia; | 1975 |
The role of technology in modern nutrition.
Topics: Adult; Child; Food Preservation; Food Supply; Food Technology; Food, Formulated; Food, Fortified; Hu | 1976 |
[Use of phenatine in complex sanatorium-health resort treatment of hypertensive disease with obesity nutritional].
Topics: Adult; Appetite Depressants; Health Resorts; Humans; Hypertension; Male; Middle Aged; Niacinamide; O | 1975 |
Further assessment of glunicate hypolipidaemic activity in the rat.
Topics: Animals; Blood Glucose; Female; Hypolipidemic Agents; Lipids; Male; Niacin; Niacinamide; Obesity; Ra | 1985 |
[The action of nicotinamide on the adenine nucleotide system as well as on mitochondrial oxidation and phosphorylation processes in the liver of db/db strain mice].
Topics: Adenine Nucleotides; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 1; Mice; Mice, Inbred C57BL | 1988 |
Effect of obesity in the rat on renal transport of organic acids and bases.
Topics: Age Factors; Aminohippuric Acids; Animals; Biological Transport; Body Weight; Carbon Isotopes; Dieta | 1973 |
Factors contributing to depressed renal transport of organic anions in the obese rat.
Topics: Age Factors; Aminohippuric Acids; Animals; Biological Transport; Dietary Fats; In Vitro Techniques; | 1973 |
Cytotoxic effects of streptozotocin and N-nitrosomethylurea on the pancreatic B cells with special regard to the role of nicotinamide-adenine dinucleotide.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Female; Glucose; Hyperglycemia; Insulin; Insulin Sec | 1974 |